RxDoctor Payments Data

Matthew Ellis

Medical Oncology · Houston, TXNPI 1669495685

Payments from drug & device makers

$289,220in general payments, 2019–2025

Across 49 payments — averaging $5902.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nanostring Technologies, Inc.$267K
  • Eli Lilly$7K
  • Novartis$6K
  • Astrazeneca UK Limited$4K
  • Veracyte, Inc.$3K
  • Covis Pharma GmbH$750
  • plus $560 from 5 others
$875in research payments, 2019–2025

Across 1 payment — averaging $875.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$875

What the payments were for

  • Royalty or licence$267,24392%
  • Consulting fees$18,6736%
  • Speaking & faculty fees$2,7001%
  • Food & beverage$4370%
  • Education$1680%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Nanostring Technologies, Inc.6$267,243
Eli Lilly6$7,483
Novartis2$6,375
Astrazeneca UK Limited3$4,110
Veracyte, Inc.7$2,700
Covis Pharma GmbH1$750
AstraZeneca5$306
Pfizer16$167
AbbVie1$58
Sumitomo Pharma America, Inc.1$18
Gilead1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$289,220 in reported general payments places this provider in the 60th percentile of 495 medical oncology providers in Texas.

See all medical oncology providers in Texas

Other medical oncology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →